Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Gastroenterol Res Pract ; 2012: 190708, 2012.
Article in English | MEDLINE | ID: mdl-21776251

ABSTRACT

Background. Due to the predominantly advanced stage at the time of diagnosis treatment of cholangiocarcinoma is difficult. Apart from surgical resection, interventional treatment strategies are increasingly used in advanced stage tumours. The aim of the study was a retrospective comparison of the effect of the various forms of treatment on morbidity and mortality. Method. A total of 195 patients, received either chemotherapy or a combination of photodynamic therapy (PDT) or transarterial chemoembolization (TACE) and chemotherapy. Results. The median survival rate for all patients was 15.6 months, 50.8% were still alive 1 year after diagnosis. Patients, who had previously undergone surgery, survived 17.1 months longer than those without surgical treatment (P < .01). Chemotherapy prolonged the survival by 9.2 months (P = .47). Palliative patients under combination of chemotherapy and PDT survived on average 1.8 months longer (P = .28), with chemotherapy and TACE 9.8 months longer (P = .04) compared to chemotherapy alone. Conclusions. It appears that surgical treatment and chemotherapy combined with PDT or TACE may prolong survival.

2.
Ann Oncol ; 18(9): 1518-22, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17761708

ABSTRACT

BACKGROUND: Current guidelines recommend screening colonoscopy in first-degree relatives of patients with colon cancer. The aim of this state-wide study was to investigate the compliance for colonoscopic in first-degree relatives, who were younger than 60 years of age. METHODS: A total of 602 patients were identified from the tumor registry of the public health insurance of Lower Saxony. A questionnaire was sent to these patients, which included a number of different questions regarding their knowledge about the risk of colon cancer for their family members, as well as their participation in screening colonoscopy. RESULTS: Data from 442 patients and their first-degree relatives (1005 siblings and 354 parents) were available; 178 parents had undergone screening colonoscopy and 344 siblings. Interestingly, the percentage of siblings who underwent screening colonoscopy was significantly higher (27%) among those siblings where the index patients were aware of the increased risk for the first-degree relatives, in contrast to the siblings of the index patients who were not aware of this risk (20%). CONCLUSION: This study demonstrates that only a minority of first-degree relatives undergo screening colonoscopy and that informing patients about the potential risk for their relatives will increase participation in screening colonoscopy in first-degree relatives of the patients.


Subject(s)
Colonoscopy , Colorectal Neoplasms/epidemiology , Patient Compliance , Adult , Colorectal Neoplasms/genetics , Family Health , Genetic Predisposition to Disease , Humans , Middle Aged , Parents , Siblings , Surveys and Questionnaires
3.
Br J Cancer ; 92(10): 1862-8, 2005 May 23.
Article in English | MEDLINE | ID: mdl-15870713

ABSTRACT

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child-Pugh score B or C) and a score of >2. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.


Subject(s)
Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic , Liver Neoplasms/pathology , Registries/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/therapy , Ethanol/administration & dosage , Ethanol/therapeutic use , Female , Humans , Liver Cirrhosis/etiology , Liver Neoplasms/complications , Liver Neoplasms/therapy , Male , Middle Aged , Prognosis , Retrospective Studies , Solvents/administration & dosage , Solvents/therapeutic use , Survival Analysis , Venous Thrombosis
SELECTION OF CITATIONS
SEARCH DETAIL
...